ondansetron has been researched along with Substance-Related Disorders in 8 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Substance-Related Disorders: Disorders related to substance use or abuse.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This requirement may reflect a necessary dosing regimen towards normalizing underlying dysfunctional neural circuits and "addiction memory" states." | 2.48 | Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy. ( Beyer, WF; Fowler, JC; Lee, TH; Mangum, OB; Mannelli, P; Patkar, A; Szabo, ST; Wetsel, WC, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Paino, M | 1 |
| Aletraris, L | 1 |
| Roman, PM | 1 |
| Lee, TH | 1 |
| Szabo, ST | 1 |
| Fowler, JC | 1 |
| Mannelli, P | 1 |
| Mangum, OB | 1 |
| Beyer, WF | 1 |
| Patkar, A | 1 |
| Wetsel, WC | 1 |
| Soyka, M | 1 |
| Kranzler, HR | 1 |
| Berglund, M | 1 |
| Gorelick, D | 1 |
| Hesselbrock, V | 1 |
| Johnson, BA | 1 |
| Möller, HJ | 1 |
| Sell, LA | 1 |
| Cowen, PJ | 1 |
| Robson, PJ | 1 |
| Mizoguchi, H | 2 |
| Suzuki, T | 2 |
| Misawa, M | 2 |
| Shirayama, N | 1 |
| Tsuda, M | 1 |
| Yoshiike, M | 1 |
| Goudie, AJ | 1 |
| Leathley, MJ | 1 |
| Jasinski, DR | 1 |
| Preston, KL | 1 |
| Testa, M | 1 |
| Sullivan, JT | 1 |
2 reviews available for ondansetron and Substance-Related Disorders
| Article | Year |
|---|---|
Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.
Topics: Animals; Behavior Therapy; Central Nervous System Sensitization; Central Nervous System Stimulants; | 2012 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Di | 2008 |
6 other studies available for ondansetron and Substance-Related Disorders
| Article | Year |
|---|---|
The use of off-label medications in substance abuse treatment programs.
Topics: Accreditation; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antiemetics; Baclofen; Clonidi | 2020 |
Ondansetron and opiate craving. A novel pharmacological approach to addiction.
Topics: Female; Humans; Male; Methadone; Narcotics; Ondansetron; Substance Withdrawal Syndrome; Substance-Re | 1995 |
Effects of serotonergic anxiolytics on physical dependence on diazepam in mice.
Topics: Animals; Anti-Anxiety Agents; Buspirone; Carbolines; Diazepam; Drug Synergism; Epilepsy, Tonic-Cloni | 1993 |
Potentiation of physical dependence on diazepam by ondansetron in rats.
Topics: Animals; Body Weight; Diazepam; Drug Synergism; Male; Ondansetron; Rats; Rats, Inbred F344; Substanc | 1994 |
Effects of the 5-HT3 antagonist ondansetron on benzodiazepine-induced operant behavioural dependence in rats.
Topics: Animals; Chlordiazepoxide; Conditioning, Operant; Female; Ondansetron; Rats; Rats, Wistar; Reinforce | 1992 |
Evaluation of the 5HT3 antagonist ondansetron (O) for cocaine (C)-like activity and abuse potential.
Topics: Cocaine; Humans; Imidazoles; Ondansetron; Substance-Related Disorders | 1990 |